KPI data tables
Lonza operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Integrated Biologics | Advanced Synthesis | Specialized Modalities |
|---|---|---|---|
| H1 2026 | 0.231 | 0.153 | 0.094 |
| H2 2025 | 0.227 | 0.16 | 0.176 |
| H1 2025 | 0.224 | 0.145 | 0.182 |
Source: Lonza Half-Year Report 2026 Note 3 (22 Jul 2026) https://www.lonza.com/-/media/39523D97F3B24D6C9664FB75A9555D00. H1 2026 CapEx Integrated Biologics 231 / Advanced Synthesis 153 / Specialized Modalities 94 / Corporate 52 / continuing 530. H1 2025 restated 224 / 145 / 182 / 91 / 642. Full-Year Report 2025 Note 3 https://www.lonza.com/-/media/Lonza/Lonzacom/investor-relations/Financial%20Reports/29012026_full_year_report. FY 2025 451 / 305 / 358 / 163 / continuing 1,277. FY 2024 restated 607 / 274 / 262 / 178 / continuing 1,321. H1 2026 presentation CapEx as % of sales https://www.lonza.com/-/media/DCE06B022C6E44BBA556AC1BF49FA248.
| Period | Integrated Biologics | Advanced Synthesis | Specialized Modalities |
|---|---|---|---|
| FY 2025 | 3.649 | 1.611 | 1.034 |
| FY 2024 | 2.883 | 1.323 | 1.099 |
Source: Lonza Full-Year Report 2025, unaudited condensed financials and Note 3 Operating Segments (28 Jan 2026), https://www.lonza.com/-/media/Lonza/Lonzacom/investor-relations/Financial%20Reports/29012026_full_year_report. FY 2025 third-party sales Integrated Biologics 3,649 / Advanced Synthesis 1,611 / Specialized Modalities 1,034. FY 2024 restated 2,883 / 1,323 / 1,099. Continuing business 6,531 and 5,480. Vacaville around CHF 0.6 billion in the Integrated Biologics narrative. FY 2025 news release https://www.lonza.com/news/2026-01-28-06-30. Reporting Center https://www.lonza.com/investor-relations/reporting-center.
| Period | Integrated Biologics | Advanced Synthesis | Specialized Modalities |
|---|---|---|---|
| H1 2026 | 1.87 | 0.834 | 0.553 |
| H2 2025 | 1.836 | 0.955 | 0.56 |
| H1 2025 | 1.813 | 0.656 | 0.474 |
Source: Lonza Half-Year Report 2026, Note 3 Operating Segments (22 Jul 2026), https://www.lonza.com/-/media/39523D97F3B24D6C9664FB75A9555D00. H1 2026 third-party sales Integrated Biologics 1,870 / Advanced Synthesis 834 / Specialized Modalities 553. H1 2025 restated 1,813 / 656 / 474 (Advanced Synthesis restated after a site moved to CHI). Continuing sales 3,374 and 3,034. FY 2025 platform totals from Full-Year Report 2025 https://www.lonza.com/-/media/Lonza/Lonzacom/investor-relations/Financial%20Reports/29012026_full_year_report. H2 2025 group print of 3,500 in Full-Year Results 2025 presentation https://cdn.prod.nntech.io/company-events/reports/7f38f3bf-4e2f-39c4-9db0-1112836fb87b/presentation.pdf. H1 2026 news https://www.lonza.com/news/2026-07-22-06-30.